Immunicom Inc, based in San Diego, CA, is a pioneering company that specializes in developing novel immunotherapies using their breakthrough Immunopheresis technology platform. Their innovative approach involves the use of a therapeutic device that works outside the body to treat various diseases, including cancer, inflammatory, renal, and autoimmune diseases. Immunicom's mission is to improve patients' quality of life and expedite their path to a healthy future by removing barriers from the blood that hinder the immune system's ability to function effectively.
With ongoing clinical trials at renowned hospitals worldwide, Immunicom is at the forefront of evaluating Immunopheresis as a singular therapy and in combination with other treatments for different types of cancer. Their LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe. While their therapies are investigational and not yet approved by the US Food and Drug Administration, Immunicom's groundbreaking approach holds great potential for transforming the field of immunotherapy and improving patient outcomes.
Generated from the website